4170 Stock Overview
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vectorite Biomedical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$15.35 |
| 52 Week High | NT$27.20 |
| 52 Week Low | NT$14.40 |
| Beta | 0 |
| 1 Month Change | -4.06% |
| 3 Month Change | 2.68% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -53.89% |
| Change since IPO | -75.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4170 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 2.3% | 2.0% | 4.0% |
| 1Y | n/a | -24.4% | 28.5% |
Return vs Industry: Insufficient data to determine how 4170 performed against the TW Biotechs industry.
Return vs Market: Insufficient data to determine how 4170 performed against the TW Market.
Price Volatility
| 4170 volatility | |
|---|---|
| 4170 Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4170's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 4170's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | n/a | www.vectorite.com.tw |
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It offers cell preparation product manufacturing; and collection, processing, and storage management of immune cells. The company’s cell preparation products are used in the field of infectious diseases and inflammation, cancer, and tumor diseases.
Vectorite Biomedical Inc. Fundamentals Summary
| 4170 fundamental statistics | |
|---|---|
| Market cap | NT$671.89m |
| Earnings (TTM) | -NT$6.60m |
| Revenue (TTM) | NT$55.85m |
12.0x
P/S Ratio-101.8x
P/E RatioIs 4170 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4170 income statement (TTM) | |
|---|---|
| Revenue | NT$55.85m |
| Cost of Revenue | NT$39.43m |
| Gross Profit | NT$16.42m |
| Other Expenses | NT$23.02m |
| Earnings | -NT$6.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 29.40% |
| Net Profit Margin | -11.82% |
| Debt/Equity Ratio | 0% |
How did 4170 perform over the long term?
See historical performance and comparison